The Indian Drugs Manufacturing Association (IDMA) and the US Food and Drug Administration (FDA) have partnered to better understand regulatory policies that are practised by the US FDA, along with promoting the adoption of advanced production technologies. The IDMA is the leading body of pharmaceutical companies in India and it represents more than 3,500 members.
As part of this partnership, the two companies will undertake a two-day workshop in the upcoming months. This workshop will be focusing on sensitising the drug manufacturing companies within the country, and it will be held on September 12 and 13, 2022.
Along with the members of the IDMA, the Department of pharmaceuticals, the secretary, and the drugs Controller General of India have attended the event. Apart from the sensitisation of the regulations in the United States, this workshop will also discuss topics such as support and guidance for the adoption of advanced production technologies for Indian pharmaceutical companies.
India is one of the largest exporters of medicine, drugs, and several other biologics to the United Sates. The US FDA has an on-site presence in New Delhi, India at the US Embassy. The office of the FDA in India is one of the four global operations, that the US FDA has.